[Effect of glutamine on serum interleukin-8 and tumor necrosis factor-alpha levels in patients with severe pancreatitis].
OBJECTIVE
To observe the changes in serum interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) after intravenous administration of alanyl-glutamine (Gln) in patients with severe pancreatitis.


METHODS
Fifty patients with severe pancreatitis were randomized equally into 2 groups and received standard total parenteral nutrition (TPN) with intravenous infusion of Gln or normal saline (control) for 1 week. The plasma glutamine level was measured with high-performance liquid chromatography (HPLC) in these patients one day before and on day 7 of Gln administration, and the serum IL-8, TNF-alpha and heat shock protein 70 (Hsp70) were detected with enzyme-linked immunosorbent assay.


RESULTS
On day of Gln administration, the plasma glutamine level in patients of Gln group increased significantly (P<0.01), and serum IL-8 and TNF-alpha levels decreased significantly (P>0.05) in comparison with those of the control group. The patients receiving Gln supplementation had significantly higher serum albumin level and greater body fat content with shorter hospital stay than those in the control group (P<0.05), and the mortality rate in Gln group was also significantly lower (P<0.05).


CONCLUSIONS
Gln-enriched TPN may improve the clinical outcomes of patients with severe pancreatitis probably by decreasing serum IL-8 and TNF-alpha levels.
Yang
Si-Qing
SQ
Department of General Surgery, Heyuan People's Hospital, Heyuan 517000, China.
Xu
Jian-Guo
JG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004151:Dipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D016209:Interleukin-8 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019283:Pancreatitis, Acute Necrotizing / Q000097:blood / Q000188:drug therapy*; D010289:Parenteral Nutrition, Total / Q000379:methods; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D055815:Young Adult
D004151:Dipeptides; D018840:HSP70 Heat-Shock Proteins; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; C054122:alanylglutamine